Cidara Therapeutics, Inc. (CDTX)
NASDAQ$22.05
Market Cap
$241.52M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
286 of 924
Rank in Industry
164 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CDTX Insider Trading Activity
CDTX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $105,680 | 1 | 20 |
Sells | $96,814 | 4 | 80 |
Related Transactions
| Stein Jeffrey | President & CEO | 1 | $105,680 | 0 | $0 | $105,680 |
| Sandison Taylor | Chief Medical Officer | 0 | $0 | 1 | $10,752 | $-10,752 |
| Ward Shane | COO & CLO | 0 | $0 | 1 | $36,542 | $-36,542 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 2 | $49,520 | $-49,520 |
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its …
Insider Activity of Cidara Therapeutics, Inc.
Over the last 12 months, insiders at Cidara Therapeutics, Inc. have bought $105,680 and sold $96,814 worth of Cidara Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cidara Therapeutics, Inc. have bought $207,124 and sold $66,716 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Stein Jeffrey (President & CEO) — $105,680.
The last purchase of 8,000 shares for transaction amount of $105,680 was made by Stein Jeffrey (President & CEO) on 2024‑06‑07.
List of Insider Buy and Sell Transactions, Cidara Therapeutics, Inc.
| 2025-03-11 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 1,773 0.0169% | $21.96 | $38,940 | +6.48% | |
| 2025-03-11 | Sale | Ward Shane | COO & CLO | 1,664 0.0159% | $21.96 | $36,542 | +6.48% | |
| 2024-09-11 | Sale | Sandison Taylor | Chief Medical Officer | 924 0.0128% | $11.64 | $10,752 | +71.60% | |
| 2024-09-11 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 909 0.0126% | $11.64 | $10,580 | +71.60% | |
| 2024-06-07 | Stein Jeffrey | President & CEO | 8,000 0.1804% | $13.21 | $105,680 | +2.10% | ||
| 2024-03-11 | Sale | Sandison Taylor | Chief Medical Officer | 20,662 0.0231% | $0.67 | $13,839 | -0.98% | |
| 2024-03-11 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 21,029 0.0235% | $0.67 | $14,085 | -0.98% | |
| 2024-03-11 | Sale | Shah Preetam | CFO & CBO | 18,931 0.0212% | $0.67 | $12,680 | -0.98% | |
| 2024-03-11 | Sale | Ward Shane | COO & CLO | 20,473 0.0229% | $0.67 | $13,713 | -0.98% | |
| 2023-09-11 | Sale | Sandison Taylor | Chief Medical Officer | 18,793 0.0205% | $0.95 | $17,810 | -27.31% | |
| 2023-09-11 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 18,469 0.0202% | $0.95 | $17,509 | -27.31% | |
| 2023-08-14 | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 10,000 0.0118% | $0.97 | $9,700 | -21.90% | ||
| 2023-08-08 | Stein Jeffrey | President & CEO | 50,000 0.0566% | $0.96 | $47,885 | -23.43% | ||
| 2023-03-27 | Stein Jeffrey | President & CEO | 50,000 0.0653% | $1.04 | $51,855 | -9.78% | ||
| 2023-03-13 | Sale | Sandison Taylor | Chief Medical Officer | 7,203 0.0081% | $1.53 | $11,021 | -45.66% | |
| 2023-03-13 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 7,562 0.0085% | $1.53 | $11,570 | -45.66% | |
| 2023-03-13 | Sale | Shah Preetam | CFO & CBO | 6,648 0.0075% | $1.53 | $10,171 | -45.66% | |
| 2023-03-13 | Sale | Ward Shane | COO & CLO | 4,329 0.0049% | $1.53 | $6,623 | -45.66% | |
| 2023-01-12 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 11,814 0.015% | $1.20 | $14,177 | -13.33% | |
| 2022-09-19 | Sale | Shah Preetam | CFO & CBO | 15,642 0.0226% | $0.77 | $12,035 | +38.16% |
Total: 70
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Stein Jeffrey | President & CEO | 24580 0.2244% | $541,989.00 | 16 | 0 | <0.0001% |
| Sandison Taylor | Chief Medical Officer | 23067 0.2106% | $508,627.35 | 2 | 5 | +18.64% |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER | 16215 0.148% | $357,540.75 | 1 | 8 | <0.0001% |
| BIOTECH TARGET N V | 10 percent owner | 2295272 20.9547% | $50.61M | 1 | 0 | <0.0001% |
| Shah Preetam | CFO & CBO | 227210 2.0743% | $5.01M | 1 | 3 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$21,574,635 | 88 | 2.81% | $217.93M | |
$69,130,029 | 69 | 25.63% | $240.78M | |
$11,468,215 | 44 | 17.78% | $246.73M | |
$17,983,739 | 41 | 102.87% | $266.1M | |
$2,545,071 | 34 | 16.59% | $230.29M |
CDTX Institutional Investors: Active Positions
| Increased Positions | 31 | +155% | 4M | +121.04% |
| Decreased Positions | 7 | -35% | 439,366 | -13.28% |
| New Positions | 17 | New | 3M | New |
| Sold Out Positions | 4 | Sold Out | 371,469 | Sold Out |
| Total Postitions | 44 | +120% | 7M | +107.76% |
CDTX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bvf Inc/Il | $27,211.00 | 9.94% | 1.09M | +389,731 | +55.43% | 2024-12-31 |
| Ra Capital Management, L.P. | $27,211.00 | 9.94% | 1.09M | +389,716 | +55.43% | 2024-12-31 |
| Tcg Crossover Management, Llc | $25,047.00 | 9.15% | 1.01M | +1M | New | 2024-12-31 |
| Vr Adviser, Llc | $19,067.00 | 6.96% | 765,723 | +765,723 | New | 2024-12-31 |
| Bain Capital Life Sciences Investors, Llc | $17,507.00 | 6.39% | 703,080 | 0 | 0% | 2024-12-31 |
| Vivo Capital, Llc | $16,698.00 | 6.1% | 670,600 | +670,600 | New | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $9,212.00 | 3.36% | 369,954 | +327,199 | +765.29% | 2024-12-31 |
| Vanguard Group Inc | $5,416.00 | 1.98% | 217,504 | +36,969 | +20.48% | 2024-12-31 |
| Checkpoint Capital L.P. | $4,904.00 | 1.79% | 196,949 | +14,523 | +7.96% | 2024-12-31 |
| Renaissance Technologies Llc | $2,381.00 | 0.87% | 95,617 | -2,200 | -2.25% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.